Dabigatran etexilate is an oral reversible direct thrombin inhibitor that offers potential practical advantages over existing anticoagulants for the prevention of venous thromboembolism after major joint replacement surgery. These include oral administration, rapid onset of action, and a predictable anticoagulant effect that obviates the need for laboratory monitoring. Evidence from 3 phase II dose-finding trials showed that dabigatran etexilate, 100 to 300 mg daily, had similar efficacy, risk of bleeding, and tolerability compared with enoxaparin. Using pharmacokinetic modeling and taking into account efficacy/safety considerations, dabigatran etexilate 150 mg and 220 mg once daily, with a half-dose on the day of surgery, were selected for further evaluation in phase III trials. These doses were selected to ensure that the risk of bleeding did not exceed that of enoxaparin. This review discusses the rationale for selection of these dose regimens based on results from phase II trials.
Background
The need for prophylaxis against venous thromboembolism (VTE) 1-3 after major knee joint replacement is well documented. Without pharmacologic prophylaxis, VTE affects 40% to 60% of patients undergoing major joint surgery either during the usual period of hospitalization (currently 3-4 days) or postdischarge. Current guidelines therefore recommend that patients undergoing knee or hip replacement surgery should receive thromboprophylaxis such as lowmolecular-weight heparins, vitamin K antagonists, or a pentasaccharide for at least 10 days after surgery, extending to 28 to 35 days for hip replacement surgery. [1] [2] [3] However, therapy is often discontinued following hospital discharge for various treatment-related reasons including propensity for interactions with other medication or food, the need for routine coagulation monitoring, or the inconvenience of parenteral administration. 4 As a result, VTE is one of the most common causes of hospital readmission following orthopaedic surgery. [5] [6] [7] Oral agents that are effective and do not require monitoring could play an important role in increasing uptake of prophylaxis beyond hospital discharge.
Thrombin plays a central role in blood coagulation and thrombus (clot) formation, by converting fibrinogen to fibrin. Therefore, effective anticoagulation can be achieved via thrombin inhibition. 8 Direct thrombin inhibitors (DTIs) directly neutralize thrombin by occupying catalytic binding sites, fibrinogen binding sites, or both. 8 Direct thrombin inhibitors have a predictable mechanism of anticoagulation. They inhibit thrombin in both inactive fluid-phase and stabilized fibrin-bound states, as well as any thrombin already bound to surfaces and neutralize further progression of thrombus growth. 9 Dabigatran etexilate is a novel, oral, reversible DTI in advanced clinical development for the prophylaxis and treatment of thromboembolic disorders. Dabigatran etexilate has a predictable pharmacokinetic/pharmacodynamic profile that permits fixed dosing and does not require coagulation monitoring. This suggests that dabigatran etexilate may overcome the limitations of parenteral anticoagulants for thromboprophylaxis after major joint replacement surgery.
This review discusses how results from the phase II dose-finding trials of dabigatran etexilate for VTE prophylaxis in patients undergoing major joint replacement provided an evidence-based rationale for the selection of appropriate dose regimens for further clinical development.
Clinical Studies
The pharmacokinetic profile of dabigatran etexilate was established by studies in healthy volunteers. Dabigatran etexilate is rapidly absorbed, with maximum plasma concentration (C max ) achieved 1.25 to 3 hours after oral administration, 10 a time-course similar to that reported with low-molecular-weight heparins. 11 The conversion of dabigatran etexilate to dabigatran occurs in various sites in the body by rapid esterase-catalyzed hydrolysis and is neither dependent on the cytochrome P450 enzyme system nor localized to the liver. 12 Dabigatran is not metabolized 12 and does not inhibit cytochrome P450 (CYP) isoenzymes in vitro 12 ; therefore, it has a low potential for interactions with other drugs. Interaction studies have shown no clinically relevant interaction between dabigatran and potential concomitant medications, including diclofenac, 13 atorvastatin, 14 or digoxin. 15 The half-life of 12 to 14 hours is similar in young and elderly participants and in men or women. 10, 16, 17 Dabigatran etexilate is largely excreted unchanged in the urine (80%); the remaining 20% is conjugated with glucuronic acid to form acylglucuronides, which are predominantly excreted via the bile. 16 Because dabigatran has predictable pharmacokinetics and pharmacodynamics and a low propensity for drug interactions, it is unlikely to require monitoring.
Based on these early studies, 3 phase II dosefinding clinical trials involving over 2000 patients were conducted to determine the optimal dose regimen for dabigatran etexilate in patients undergoing primary elective hip and knee replacement surgery (Table 1) . [18] [19] [20] Male or female patients 18 years or older, weighing at least 40 kg, who provided written informed consent were included in the trials. Those patients with known liver and renal disease or risk of bleeding were excluded from participation. In all 3 studies, the primary efficacy outcome was total VTE during the treatment period, defined as a composite of venographically documented deep vein thrombosis (DVT), symptomatic DVT, and pulmonary embolism (PE). The primary safety outcome was the incidence of major bleeding (including bleeds at the surgical site). Other bleeding outcomes included clinically relevant nonmajor bleeding (see Table 2 ). All bleeding events were classified by an independent adjudication committee.
Proof-of-Principle Study
The first of these phase II trials (Boehringer Ingelheim Study in ThROmbosis [BISTRO I]) was an open-label, phase IIa, multicenter (11 sites in Sweden, 7 in Norway) dose-escalation study of dabigatran etexilate in 314 patients undergoing hip replacement surgery. 18 The aim of the study was to determine a safe therapeutic dose range for further evaluation. Patients received 1 of 9 doses of dabigatran etexilate (12.5, 25, 50, 100, 150, 200 , and 300 mg twice daily or 150 and 300 mg once daily as a preliminary oral tablet formulation). The first dose was administered 4 to 8 hours after surgery or delayed until the following morning in the event of vomiting or active bleeding. Treatment was continued for 6 to 10 days or until mandatory, standardized, bilateral venography was performed.
In the study, no major bleeding episodes occurred at any of the doses studied, although 2 patients receiving the highest dose (300 mg twice daily) experienced bleeding from multiple sites within a few days of treatment. In both patients, trough plasma concentrations for dabigatran etexilate were 3-to 5-fold higher than geometric mean concentrations for that treatment group and were associated with substantial prolongation of activated partial thromboplastin time. This dose was therefore considered to be at or above the maximum tolerable dose for this patient group, leading to cessation of dose escalation. The lack of any major bleeding events in the trial may be explained by exclusion from analysis of bleeding events that occurred during the perioperative period prior to the first dose of dabigatran etexilate. In addition, investigators were advised to record clinically overt bleeding episodes at the surgical site only if considered excessive or unexpected based on their usual practice. The frequency of minor bleeding episodes (ie, all other bleeding events including, for example, hematoma, urinary bleeding, nose bleeding, and prolonged bleeding after vein puncture) did show a significant dose-proportional increase suggesting that dabigatran etexilate was exerting its expected pharmacologic dose-response. This definition differed slightly from those used in other trials, and therefore a potentially higher number of minor bleeding events were observed. The DVT rates in BISTRO I were relatively low, ranging from 6.1% with 300 mg once daily to 20.8% with 12.5 mg twice daily (overall rate 12.4%). None of the patients developed symptomatic DVT during treatment. Thus, the study suggested that the therapeutic window for dabigatran etexilate was within this dose range. There were a number of limitations to this study, in particular, insufficient power to enable comparison of the efficacy of individual dabigatran etexilate doses. The open-label design of the study did, however, enable prompt transfer of information from the investigators to the steering committee to assist in clinical decisions regarding dose escalation.
It was notable that about 20% of patients in the trial had low plasma concentrations of dabigatran after the first dose, resulting in high interindividual variability in the pharmacokinetic parameters. In view of this, a capsule formulation with an improved pharmacokinetic profile was subsequently developed.
Single-Dose Pharmacokinetic Study
BISTRO Ib, 19 was a small, single-dose (150 mg), uncontrolled, open-label study (n ¼ 59), which compared the pharmacokinetic properties of this new capsule formulation of dabigatran etexilate with the tablet used in BISTRO I. Absorption of dabigatran etexilate in the stomach and small intestine is dependent on an acidic environment. Therefore, improving the acidic microenvironment would be expected to increase drug dissolution and absorption independent of variation in the gastric pH. 10 To achieve this, the new capsule formulation incorporated multiple pellets containing a tartaric acid core coated by dabigatran etexilate. 10 The capsule made drug dissolution more reproducible irrespective of the acidic environment. This enabled early administration of the capsule 1 to 3 hours after surgery to improve efficacy associated with early postoperative administration. As a result of improved dissolution characteristics, the capsule could be administered 1 to 3 hours following surgery compared with 4 to 8 hours postsurgery for the tablet formulation used in BISTRO I. This new formulation proved to be effective, with prompt absorption and peak plasma concentrations of dabigatran achieved 6 hours after administration. Peak plasma concentrations and systemic exposure of dabigatran with this new capsule formulation were approximately 85% of that seen in healthy volunteers at steady-state using the tablet formulation. 19 These characteristics confirmed the suitability of this capsule for use in future clinical trials.
Phase IIb Dose-Ranging Study
Subsequently, the BISTRO II trial, a large, randomized multicenter parallel-group, double-blind study was conducted to determine the efficacy/safety dose-response relationship of dabigatran etexilate in hip and knee replacement surgery. 20 A total of 1973 There was a clear dose-dependent decrease in total VTE with increasing doses of dabigatran etexilate, ranging from 28.5% with 50 mg twice daily to 13.1% with 225 mg twice daily (P ¼ .00007 vs enoxaparin). By comparison, total VTE was 24% in the enoxaparin group (Table 3) . Venous thromboembolism frequency was similar in patients receiving 300 mg once daily versus 150 mg twice daily (16.6% and 17.4%), supportive of once-daily dosing in future orthopedic prophylaxis trials. The incidence of major VTE (proximal DVT and PE) was lower with all dabigatran etexilate doses (1.7%-5.0%) than with enoxaparin (5.6%). In patients receiving the first dose of dabigatran etexilate within 2 hours after surgery, the frequency of VTE was significantly lower compared with other time points (P ¼ .0005).
Compared with enoxaparin, major bleeding (including wound site bleeding) was significantly lower with the lowest dabigatran etexilate dose (50 mg twice daily; 0.3 vs 2.0%, P ¼ .047), with an increase, albeit nonsignificant, at higher doses (3.8% to 4.7%). Post hoc analysis did not demonstrate any association between the rate of major bleeding and timing of administration of the first dose (0 to 2 hours, 2 to 4 hours, or more than 4 hours after surgery) across the range of dabigatran etexilate doses. 21 This contrasts with data reported for the parenteral anticoagulant fondaparinux, where bleeding rates were higher when the timing of administration of the first dose was closer to surgery. 22 It is likely that these results observed with dabigatran etexilate relate to pharmacokinetic characteristics on the day of surgery. In fact, evidence from BISTRO II showed that absorption of dabigatran etexilate on the day of surgery was reduced compared with subsequent days (C max at *4-6 hours vs 2 hours among patients in the highest dose group), although this did not impact on overall dabigatran exposure. 20 This pharmacokinetic profile immediately after surgery, that is, slow and prolonged absorption with lower C max may help to reduce the risk of bleeding, even when dabigatran etexilate is administered very early after surgery (Figure 1) .
Findings from BISTRO II showed that dabigatran etexilate (total daily dose 100-300 mg) appeared to be as effective as enoxaparin, although larger studies were still needed to assess the risk of bleeding. Moreover, a once-daily dosing regimen was equally effective as twice-daily dosing, with comparable rates of bleeding.
Safety and Tolerability in Phase II Trials
Dabigatran etexilate was well tolerated in these phase II trials, with a safety profile similar to that observed with enoxaparin. There was no evidence of compromised liver safety after short-term use in the postsurgical setting. Moderate increases in the concentration of alanine aminotransferase (more than 3 times the upper limit of the normal range) was generally lower with dabigatran etexilate (1.5% to 3.1%) compared with enoxaparin (7.4%). 20 Dabigatran etexilate had no effect on laboratory parameters (other than clotting tests) and early postoperative administration was associated with a low incidence of nausea and vomiting.
Dose Selection for Use in the Phase III Trial Program
A pharmacokinetic/pharmacodynamic substudy was performed on 325 patients enrolled in BISTRO II. The analyses conducted were to support informed decisions concerning dose selection and posology for phase III pivotal trials, consider the use of once versus twice-daily dosing, the timing of the first dose after surgery, and whether there was benefit in employing a reduction in the first dose after surgery. A logistic regression analysis was used to correlate the pharmacokinetic profile of dabigatran with clinical outcomes observed during the trial. The analysis noted several important findings: (1) administration of dabigatran etexilate 1 to 4 hours postoperatively was associated with a reduced risk of DVT, supporting early postoperative initiation of treatment; (2) low dabigatran concentrations were already associated with a marked reduction in the rate of DVT, indicating that dose reduction on the day of surgery is possible; (3) an increase in the risk of bleeding on day of surgery was noted with increasing dabigatran peak concentrations, supportive of a 50% reduction in the dose of dabigatran etexilate on the day of surgery, which significantly improved the safety profile; (4) the area under the plasma concentration curve (AUC) and C max of dabigatran at steady state have similar effects on safety and efficacy, indicating that AUC was useful as the primary pharmacokinetic parameter for dose selection; and (5) dabigatran trough plasma concentrations displayed the weakest relationship with safety and efficacy, supporting the use of a once-daily dosing regimen in phase III trials. Figure 2 shows the model results, comparing the AUC of dabigatran at steady state vs the DVT rate and clinically relevant bleeding events. 20 Figure 1 . Plasma concentration (mean + SD) versus time curve following the first postoperative dose (150 mg) of dabigatran etexilate compared with that observed in healthy volunteers. 19 Data from the Boehringer Ingelheim Study in ThROmbosis (BIS-TRO) Ib study 19 showed a slow and steady absorption profile on the day of surgery with reduced and delayed peak plasma concentrations approximately 6 hours following administration (8 hours following surgery). Additionally, BISTRO I showed that delayed absorption was only present on the day of surgery; thereafter absorption of dabigatran was rapid, with peak plasma concentrations attained 2 hours after drug administration. 18 Figure 2 . Thus, this model supported a dosing regimen involving administration of a half-dose of dabigatran etexilate immediately after surgery with full doses thereafter as the optimal dosing strategy based on efficacy/safety considerations. To minimize the bleeding risk in the perioperative period, doses for further evaluation in phase III trials were chosen so that the bleeding risk did not exceed that for enoxaparin. On this basis, dabigatran etexilate 150 mg and 220 mg once daily, with half doses of 75 mg and 110 mg administered on the day of surgery, were selected for use in phase III trials. Figure 3 shows the predicted plasma concentration time curves on the day of surgery and at steady state for these two doses.
Conclusions
Anticoagulation is the standard of care for prevention of VTE after major joint surgery. Although effective, current anticoagulants are inconvenient due to parenteral administration out of hospital and/or the need for anticoagulant monitoring. From a clinical perspective, the greatest obstacle to the development of a new anticoagulant for prophylaxis in this setting has been the demand for less anticoagulant-related bleeding. 23 The design of recent clinical trials evaluating new anticoagulant compounds reflects this view. Although there remains an unmet need for improved efficacy, in particular with regard to VTE-related mortality, trials have increasingly focused on the bleeding profile of these new compounds. 24 Clinical evidence from phase II trials in major joint surgery suggests that these constraints may be overcome by dabigatran etexilate, a novel, oral DTI. Dabigatran etexilate thromboprophylaxis had a similar efficacy and safety profile as recommended regimens of subcutaneously administered enoxaparin. Furthermore, when administered close to surgery, delayed absorption and reduced maximal plasma concentration decreased the risk of bleeding complications while maintaining equivalent efficacy compared with standard prophylaxis. Dabigatran etexilate can be given once daily as a fixed dose, irrespective of age, gender, or body weight, making it convenient for use across numerous indications, in both inpatient and outpatient settings. This favorable pharmacological profile, supported by phase II doseranging studies, provided the basis for selection of dabigatran etexilate dose regimens for phase III development. Figure 3 . Population pharmacokinetic predictions of dabigatran pharmacokinetic profiles with phase III target doses of 150 and 220 mg once daily (od). The above figure shows the simulated median dabigatran plasma concentration-time profiles with doses of 75 mg and 110 mg doses on the day of surgery followed by 150 mg and 220 mg once-daily doses at steady state.
